Key result
Intravenous iron supplementation in patients with HFrEF has shown favorable effects on symptoms, functional status, and heart failure hospitalizations.
Why the study?
Does intravenous (IV) iron supplementation improve symptoms, functional status, and heart failure (HF) hospitalizations in patients with heart failure and reduced ejection fraction (HFrEF)?
Does intravenous (IV) iron supplementation improve symptoms, functional status, and heart failure (HF) hospitalizations in patients with heart failure and reduced ejection fraction (HFrEF)?
Intravenous iron supplementation is an important therapeutic target in HFrEF that has shown favorable effects on symptoms, functional status, and hospitalizations.
Answers are grounded in this paper and cite their sources.
Supports the symptomatic benefits of intravenous iron in HFrEF; leaves open whether observational.
Iron deficiency is an important therapeutic target in patients with heart failure and reduced ejection fraction (HFrEF). Over the past two decades, several trials of intravenous (IV) iron supplementation in HFrEF have shown favorable effects on symptoms, functional status, and heart failure (HF) hospitalizations...
No takes yet. Share an insight, caveat, or question.
Talha et al. (2023) studied this question. Intravenous iron supplementation in patients with HFrEF has shown favorable effects on symptoms, functional status, and heart failure hospitalizations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: